Mid‑stage results for petrelintide, an amylin analog developed by Zealand with Roche, produced placebo‑adjusted weight loss of about 9.0% (10.7% mean reduction vs 1.7% placebo) at 42 weeks—below investor expectations and analyst benchmarks set by competing programs. The Phase 2 ZUPREME‑1 readout triggered a stock drop for Zealand while the company emphasized tolerability and a path to Phase 3. Roche and Zealand framed the data as demonstrating favorable safety and consistent efficacy, but analysts raised concerns about differentiation in a hypercompetitive obesity market where GLP‑1 and next‑gen candidates have set higher efficacy expectations. The results will shape dose selection and positioning ahead of planned Phase 3 work and underscore the escalating efficacy bar in anti‑obesity therapeutics.